Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Update

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 137,600 shares, a growth of 143.1% from the November 15th total of 56,600 shares. Based on an average daily volume of 51,400 shares, the days-to-cover ratio is currently 2.7 days.

Appili Therapeutics Price Performance

APLIF stock opened at $0.03 on Friday. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.05. The stock has a market capitalization of $3.12 million, a price-to-earnings ratio of -1.29 and a beta of -0.48. The business’s fifty day moving average price is $0.02 and its two-hundred day moving average price is $0.03.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.